Skip to content

News Blog / Research

Can we transform the diagnosis & treatment of ALS?

French postage stamp honoring Jean-Martin Charcot (1825–1893)

In 1874, Jean-Martin Charcot described a devastating paralytic illness which we now call ALS.

ALS cuts down people in the prime of their lives.

Only two FDA-approved drugs exist for the treatment of ALS, and neither significantly slow disease progression.

We have focused on the early diagnosis and treatment of ALS.

We discovered a molecular fingerprint of ALS, which will allow neurologists to definitively diagnose ALS based on a single blood draw. We extract microRNA from exosomes—microscopic packages of genetic material—in the blood sample. The unique assemblage of microRNA identifies ALS patients.

Currently, many patients have to wait a year or more to receive an ALS diagnosis. This new diagnostic test will allow patients to begin treatment much earlier.

Our advanced clinical trials of the naturally occurring amino acid L-serine are promising.

Hopefully, this combination of a diagnostic and a treatment package will be attractive to a pharmaceutical partner who can conduct the larger clinical trials that will be needed.

Dr. Sandra Banack preparing an ELISA plate to measure exosomes
Dr. Sandra Banack prepares an ELISA plate to measure exosomes.

More newsAll news